|1.||Desai, Avinash: 2 articles (09/2006 - 09/2003)|
|2.||Williams, Jon I: 2 articles (12/2003 - 09/2003)|
|3.||Holroyd, Kenneth J: 2 articles (12/2003 - 09/2003)|
|4.||Connolly, Brian: 1 article (09/2006)|
|5.||Garcia, Charles A: 1 article (09/2006)|
|6.||Gast, Michael J: 1 article (09/2006)|
|7.||Thomas, Edgar: 1 article (09/2006)|
|8.||Criswell, Mark H: 1 article (12/2003)|
|9.||Danis, Ronald P: 1 article (12/2003)|
|10.||Ciulla, Thomas A: 1 article (12/2003)|
12/01/2001 - "A Phase I study of squalamine, a novel antiangiogenic agent originally isolated from the dogfish shark Squalus acanthias, was conducted in patients with advanced cancers to: (a) determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of squalamine lactate when given as a 120-h continuous i.v. infusion every two weeks; and (b) to obtain information on prolonged (>120-h) continuous i.v. infusions in patients who have tolerated 120-h infusions. "
|2.||Macular Degeneration (Age-Related Maculopathy)
09/01/2006 - "A series of basic investigations, preclinical studies, and human clinical trials have begun to establish the proof of concept, efficacy, and safety parameters for use of squalamine lactate as a therapeutic agent for exudative age-related macular degeneration and several types of malignancies."
09/01/2006 - "Squalamine lactate for exudative age-related macular degeneration."
|3.||Eye Diseases (Eye Disease)
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2003 - "Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat."
12/01/2003 - "To determine if systemically administered squalamine lactate, a novel aminosterol with antineoplastic and antiangiogenic activity, inhibits the development of experimental choroidal neovascularization membranes (CNVMs) induced by laser trauma in a rat model. "